In first for European Union, anti-skin cancer drug approvedFrench pharmaceutical giant Sanofi's new tumour-reducing drug is aimed at patients with the second most common form of skin cancer whose cancer is advanced and are who are not candidates for surgery or radiation therapy. "The benefits with Libtayo are its ability to reduce tumour size and to prevent progression of the tumour for longer," it said. No drugs for the treatment of CSCC are currently approved in the EU, according to Sanofi. Final approval of the drug will be given subject to Sanofi providing further results from clinical trials. The US Food and Drug Administration (FDA) approved Libtayo in September 2018 while Health Canada gave it the conditional green light earlier this month.

Source: Standard Digital April 27, 2019 07:18 UTC